DSP 1053Alternative Names: DSP1053
Latest Information Update: 28 Aug 2014
At a glance
- Originator Dainippon Sumitomo Pharma
- Developer Sunovion Pharmaceuticals
- Class Antidepressants
- Mechanism of Action Serotonin uptake inhibitors
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
On Fast track
Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.
- New Molecular Entity Yes
Highest Development Phases
- Discontinued Depressive disorders